Selected article for: "case outcome and immune response"
Author: Bouadma, Lila; Wiedemann, Aurélie; Patrier, Juliette; Surénaud, Mathieu; Wicky, Paul-Henri; Foucat, Emile; Diehl, Jean-Luc; Hejblum, Boris P.; Sinnah, Fabrice; de Montmollin, Etienne; Lacabaratz, Christine; Thiébaut, Rodolphe; Timsit, J. F.; Lévy, Yves
Title: Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome
  • Cord-id: smnu122h
  • Document date: 2020_8_22
    • ID: smnu122h
    Snippet: We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2–3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-se
    Document: We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2–3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in γδ T cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a pro-inflammatory cytokine storm, Th1 and Th2 activation, and markers of T cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response. The investigation was conducted as part of an overall French clinical cohort assessing patients with COVID-19 and registered in clinicaltrials.gov under the following number: NCT04262921. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10875-020-00839-x) contains supplementary material, which is available to authorized users.

    Search related documents:
    Co phrase search for related documents
    • aberrant host cytokine storm and acute respiratory syndrome: 1
    • accumulation monocyte macrophage recruitment and acute lung injury: 1, 2
    • accumulation monocyte macrophage recruitment and acute respiratory syndrome: 1
    • acinetobacter baumannii and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • acinetobacter baumannii and acute kidney injury: 1, 2
    • acinetobacter baumannii and acute lung injury: 1
    • acinetobacter baumannii and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acinetobacter baumannii and adaptive innate: 1
    • acinetobacter baumannii and liver failure: 1, 2
    • acinetobacter baumannii and longitudinal analysis: 1
    • activation marker and acute ards respiratory distress syndrome: 1, 2
    • activation marker and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • activation marker and adaptive innate: 1, 2
    • activation marker and adaptive innate immunity: 1
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and longitudinal analysis: 1, 2
    • acute fever and adaptive innate: 1